Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Valgimigli Marco) "

Sökning: WFRF:(Valgimigli Marco)

  • Resultat 21-30 av 39
  • Föregående 12[3]4Nästa
Sortera/gruppera träfflistan
  • Gorenek, Bulent, et al. (författare)
  • Cardiac arrhythmias in acute coronary syndromes : position paper from the joint EHRA, ACCA, and EAPCI task force
  • 2014
  • Ingår i: EuroIntervention. - 1774-024X .- 1969-6213. ; 16, s. 1655-1673
  • Tidskriftsartikel (refereegranskat)abstract
    • It is known that myocardial ischaemia and infarction leads to severe metabolic and electrophysiological changes that induce silent or symptomatic life-threatening arrhythmias. Sudden cardiac death is most often attributed to this pathophysiology, but many patients survive the early stage of an acute coronary syndrome (ACS) reaching a medical facility where the management of ischaemia and infarction must include continuous electrocardiographic (ECG) and hemodynamic monitoring, and a prompt therapeutic response to incident sustained arrhythmias. During the last decade, the hospital locations in which arrhythmias are most relevant have changed to include the cardiac catheterization laboratory, since the preferred management of early acute ACS is generally interventional in nature. However, a large proportion of patients are still managed medically.Both atrial and ventricular arrhythmias may occur in the setting of ACS and sustained ventricular tachyarrhythmias (VAs) may be associated with circulatory collapse and require immediate treatment. Atrial fibrillation (AF) may also warrant urgent treatment when a fast ventricular rate is associated with hemodynamic deterioration. The management of other arrhythmias is also based largely on symptoms rather than to avert progression to more serious arrhythmias. Prophylactic antiarrhythmic management strategies have largely been discouraged.Although the mainstay of antiarrhythmic therapy used to rely on antiarrhythmic drugs (AADs), particularly sodium channel blockers and amiodarone, their use has now declined, since clinical evidence to support such treatment has never been convincing. Therapy for acute coronary syndrome and arrhythmia management are now based increasingly on invasive approaches. The changes in the clinical approach to arrhythmia management in ACS have been so substantial that the European Heart Rhythm Association, the Acute Cardiovascular Care Association and the European Association of Percutaneous Cardiovascular Interventions established a task force to define the current position.
  • Harrington, Robert A., et al. (författare)
  • The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA.CER) trial : study design and rationale
  • 2009
  • Ingår i: American Heart Journal. - 0002-8703 .- 1097-6744. ; 158:3, s. 327-334
  • Tidskriftsartikel (refereegranskat)abstract
    • Background The protease-activated receptor 1 (PAR-1), the main platelet receptor for thrombin, represents a novel target for treatment of arterial thrombosis, and SCH 530348 is an orally active, selective, competitive PAR-1 antagonist. We designed TRA.CER to evaluate the efficacy and safety of SCH 530348 compared with placebo in addition to standard of care in patients with non-ST-segment elevation (NSTE) acute coronary syndromes (ACS) and high-risk features. Trial design TRA.CER is a prospective, randomized, double-blind, multicenter, phase III trial with an original estimated sample size of 10,000 subjects. Our primary objective is to demonstrate that SCH 530348 in addition to standard of care will reduce the incidence of the composite of cardiovascular death, myocardial infarction (MI), stroke, recurrent ischemia with rehospitalization, and urgent coronary revascularization compared with standard of care alone. Our key secondary objective is to determine whether SCH 530348 will reduce the composite of cardiovascular death, MI, or stroke compared with standard of care alone. Secondary objectives related to safety are the composite of moderate and severe GUSTO bleeding and clinically significant TIMI bleeding. The trial will continue until a predetermined minimum number of centrally adjudicated primary and key secondary end point events have occurred and all subjects have participated in the study for at least I year. The TRA.CER trial is part of the large phase III SCH 530348 development program that includes a concomitant evaluation in secondary prevention. Conclusion TRA.CER will define efficacy and safety of the novel platelet PAR-1 inhibitor SCH 530348 in the treatment of high-risk patients with NSTE ACS in the setting of current treatment strategies.
  • Palmerini, Tullio, et al. (författare)
  • Risk-Benefit of 1-Year DAPT After DES Implantation in Patients Stratified by Bleeding and Ischemic Risk.
  • 2021
  • Ingår i: Journal of the American College of Cardiology. - 1558-3597. ; 78:20, s. 1968-1986
  • Tidskriftsartikel (refereegranskat)abstract
    • Although a 1-year duration of dual antiplatelet therapy (DAPT) is used in many patients after drug-eluting stent (DES) implantation, the evidence supporting this duration is uncertain.The authors investigated the risk-benefit profile of 1-year vs ≤6-month DAPT after DES using 2 novel scores to risk stratify bleeding and ischemic events.Ischemic and bleeding risk scores were generated from ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents), a multicenter, international, "all-comers" registry that enrolled 8,665 patients treated with DES. The risk-benefit profile of 1-year vs ≤6-month DAPT was then investigated across risk strata from an individual patient data pooled dataset of 7 randomized trials that enrolled 15,083 patients treated with DES.In the derivation cohort, the ischemic score and the bleeding score had c-indexes of 0.76 and 0.66, respectively, and both were well calibrated. In the pooled dataset, no significant difference was apparent in any ischemic endpoint between 1-year and ≤6-month DAPT, regardless of the risk strata. In the overall dataset, there was no significant difference in the risk of clinically relevant bleeding between 1-year and ≤6-month DAPT; however, among 2,508 patients at increased risk of bleeding, 1-year compared with ≤6-month DAPT was associated with greater bleeding (HR: 2.80; 95% CI: 1.12-7.13) without a reduced risk of ischemic events in any risk strata, including those with acute coronary syndromes. These results were consistent in a network meta-analysis.In the present large-scale study, compared with ≤6-month DAPT, a 1-year duration of DAPT was not associated with reduced adverse ischemic events in any risk strata (including acute coronary syndromes) but was associated with greater bleeding in patients at increased risk of bleeding.
  • Roth, Gregory A, et al. (författare)
  • Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019 : Update From the GBD 2019 Study
  • 2020
  • Ingår i: Journal of the American College of Cardiology. - 0735-1097 .- 1558-3597. ; 76:25, s. 2982-3021
  • Tidskriftsartikel (refereegranskat)abstract
    • Cardiovascular diseases (CVDs), principally ischemic heart disease (IHD) and stroke, are the leading cause of global mortality and a major contributor to disability. This paper reviews the magnitude of total CVD burden, including 13 underlying causes of cardiovascular death and 9 related risk factors, using estimates from the Global Burden of Disease (GBD) Study 2019. GBD, an ongoing multinational collaboration to provide comparable and consistent estimates of population health over time, used all available population-level data sources on incidence, prevalence, case fatality, mortality, and health risks to produce estimates for 204 countries and territories from 1990 to 2019. Prevalent cases of total CVD nearly doubled from 271 million (95% uncertainty interval [UI]: 257 to 285 million) in 1990 to 523 million (95% UI: 497 to 550 million) in 2019, and the number of CVD deaths steadily increased from 12.1 million (95% UI:11.4 to 12.6 million) in 1990, reaching 18.6 million (95% UI: 17.1 to 19.7 million) in 2019. The global trends for disability-adjusted life years (DALYs) and years of life lost also increased significantly, and years lived with disability doubled from 17.7 million (95% UI: 12.9 to 22.5 million) to 34.4 million (95% UI:24.9 to 43.6 million) over that period. The total number of DALYs due to IHD has risen steadily since 1990, reaching 182 million (95% UI: 170 to 194 million) DALYs, 9.14 million (95% UI: 8.40 to 9.74 million) deaths in the year 2019, and 197 million (95% UI: 178 to 220 million) prevalent cases of IHD in 2019. The total number of DALYs due to stroke has risen steadily since 1990, reaching 143 million (95% UI: 133 to 153 million) DALYs, 6.55 million (95% UI: 6.00 to 7.02 million) deaths in the year 2019, and 101 million (95% UI: 93.2 to 111 million) prevalent cases of stroke in 2019. Cardiovascular diseases remain the leading cause of disease burden in the world. CVD burden continues its decades-long rise for almost all countries outside high-income countries, and alarmingly, the age-standardized rate of CVD has begun to rise in some locations where it was previously declining in high-income countries. There is an urgent need to focus on implementing existing cost-effective policies and interventions if the world is to meet the targets for Sustainable Development Goal 3 and achieve a 30% reduction in premature mortality due to noncommunicable diseases.
Skapa referenser, mejla, bekava och länka
  • Resultat 21-30 av 39
  • Föregående 12[3]4Nästa
Typ av publikation
tidskriftsartikel (38)
forskningsöversikt (1)
Typ av innehåll
refereegranskat (37)
övrigt vetenskapligt (2)
Valgimigli, Marco (39)
Windecker, Stephan (13)
Huber, Kurt (13)
Steg, Philippe Gabri ... (10)
James, Stefan, 1964- (9)
Mehran, Roxana (9)
visa fler...
Kastrati, Adnan (9)
Widimsky, Petr (8)
Jüni, Peter (8)
Wallentin, Lars (8)
Storey, Robert F. (8)
Roffi, Marco (7)
Bhatt, Deepak L (7)
Mahaffey, Kenneth W. (7)
Montalescot, Gilles (7)
Byrne, Robert A. (7)
Collet, Jean-Philipp ... (6)
Kolh, Philippe (6)
Vranckx, Pascal (6)
Kim, Hyo-Soo (6)
Bueno, Héctor (5)
Harrington, Robert A (5)
Blomström-Lundqvist, ... (5)
Van de Werf, Frans (5)
Armstrong, Paul W. (5)
Halvorsen, Sigrun (5)
Tricoci, Pierluigi (5)
White, Harvey D. (5)
Angiolillo, Dominick ... (5)
Moliterno, David J. (5)
Gibson, C. Michael (5)
Morice, Marie-Claude (5)
Knuuti, Juhani (4)
Hindricks, Gerhard (4)
Stone, Gregg W. (4)
James, Stefan K (4)
Cornel, Jan H. (4)
Jeppsson, Anders, 19 ... (4)
Chen, Edmond (4)
James, Stefan K., 19 ... (4)
Cuisset, Thomas (4)
Strony, John (4)
Hamm, Christian W. (4)
Haude, Michael (4)
Kimura, Takeshi (4)
Colombo, Antonio (4)
Capodanno, Davide (4)
Rao, Sunil V (4)
Urban, Philip (4)
Bode, Christoph (4)
visa färre...
Uppsala universitet (32)
Göteborgs universitet (5)
Karolinska Institutet (3)
Lunds universitet (2)
Linnéuniversitetet (1)
Engelska (39)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (26)


Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy